Professor M. Ghoneum reports on the latest research results on BioBran at the Federation of Clinical Immunology Societies (FOCiS 2007)

Professor M. Ghoneum reports on the latest research results on BioBran at the Federation of Clinical Immunology Societies (FOCiS 2007)

One of the developers of the Daiwa Pharmaceutical's major product “BioBran,” Prof. M. Ghoneum (Professor of Immunology at Drew University of Medicine and Science in Los Angeles) presented the latest research results concerning BioBran at the meeting of the Federation of Clinical Immunology Society (FOCiS 2007) held in San Diego in June.

FOCiS was established as a federation integrating clinical societies concerned with immunology in the United States and worldwide with the idea “to improve human health through immunology.” In poster presentations and workshops, a variety of subjects related to immunology are discussed in depth. Prof. Ghoneum, who participated in the meeting last year, was also present at this year's meeting and made a presentation entitled “Rice Bran Supplement (BioBran) Suppresses Tumor Growth via Modulating Cytokine Production and Increasing Apoptotic Level in Ehrlich Carcinoma-Bearing Mice,” the summary of which is shown below:

in vivo This study was undertaken to investigate the in vivo anti-tumor activity of BioBran and the mechanisms underlying its effect. Mice were inoculated intramuscularly in the right thigh with Ehrlich ascites carcinoma (EAC) cells. At day 8, mice bearing solid Ehrlich carcinoma tumor (SEC) were treated with BioBran (40 mg/kg body weight) via intraperitoneal injection, 3 times/week, until day 35. Tumor growth (volume and weight), plasma cytokine production, and the apoptotic effect of BioBran were examined. Injection of BioBran caused a highly significant growth delay in both tumor volume and tumor weight compared with controls. The mechanisms by which BioBran exerts its anti-tumor effect seem to involve plasma cytokine production. The levels of IFNγ and TNFa were increased compared with control mice bearing SEC, while the levels of the immune suppressing cytokine IL-10 were down-regulated. In addition, BioBran induced a 1.8-fold increase in the percentage of apoptotic SEC cells as determined by flow cytometry and histopathological examination. No adverse side effects due to BioBran treatment were observed and all animals displayed normal feeding/drinking and life activity patterns with a significant body weight gain. These data may have clinical implications for the treatment of solid cancers.

Prof. Ghoneum is one of the foremost authorities on the research into fields such as NK cells and cancers, stress, and aging and has published over 200 papers. In 2002, he was selected as one of the “INTERNATIONAL SCIENTISTS OF THE YEAR 2002” by the International Biographical Centre in the U.K. for his contributions to immunology.

Daiwa's BioBran holds a process patent in 9 countries, including Japan, the United States, and European counties. With a wide range of accumulated evidence and ISO/HACCP certification for its production process, BioBran has established a strong position as a functional food originating in Japan and is sold in 40 countries worldwide.

・